METTL3 and neoplasm: Li et al. (2022) revealed that METTL3 stabilizes ZNF677 mRNA via IGF2BP2- and YTHDF1-dependent m6A modifications, enhancing its translation. Elevated ZNF677 levels transcriptionally repress CDKN3 (cyclin-dependent kinase inhibitor 3), a driver of cell cycle progression, thereby inhibiting ccRCC proliferation and metastasis. This pathway underscores the therapeutic value of METTL3 modulation in restoring tumor suppressor activity (Table 2).